Öztürk, Savaş, Karadağ, Serhat, Arıcı, Mustafa, Türkmen, Aydın, Turgutalp, Kenan, Aktaş, Nimet, Kazancıoğlu, Rümeyza, Kuzu, Tolga, Öztürk, İlyas, Aydın, Zeki, Ayar, Yavuz, Mutluay, Rüya, Ebinç, Fatma Ayerden, Pınar, Musa, Bastürk, Taner, Yılmaz, Fatih, İnci, Ayça, Trabulus, Sinan, Ural, Zeynep, and Pembegül, İrem
Background: Patients with chronic diseases such as chronic kidney disease (CKD) have been reported to have more adverse outcomes during the coronavirus disease 2019 (COVID-19) pandemic. There are insuficient data on the outcomes of patients with primary glomerular diseases (PGD) afer COVID-19. Methods: We designed a national multicenter observational study that included adult patients with biopsy-proven PGD who survived COVID-19. A control group was created from the same centers, including PGD patients without COVID-19. The clinical and laboratory data of the patients at baseline, frst, and third months afer COVID-19 were recorded. Results: A total of 129 patients from 21 centers were included (COVID-19 group, n = 77). Baseline characteristics were almost similar except the ratio of active disease in the non-COVID-19 group was signifcantly higher than in the COVID-19 group. No patients died during the frst and third months. Respiratory symptoms were signifcantly higher in the COVID-19 group than in the non-COVID-19 group in the frst month (7.8% vs. 0%, P = .039). All other follow-up outcomes, including initiation of chronic kidney replacement therapy and initiation of new immunosuppressive treatment, and the laboratory data were not diferent between the groups in the frst and third months. Conclusion: Primary glomerular disease patients in the post-COVID-19 period had more respiratory symptoms than non-COVID-19 PGD patients, but outcomes, including death and initiation of kidney replacement therapy, were not diferent in the frst and third months post COVID-19. [ABSTRACT FROM AUTHOR]